<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002971</url>
  </required_header>
  <id_info>
    <org_study_id>NABTC-9702</org_study_id>
    <secondary_id>CDR0000065479</secondary_id>
    <secondary_id>NCI-T96-0103</secondary_id>
    <nct_id>NCT00002971</nct_id>
  </id_info>
  <brief_title>O(6)-Benzylguanine in Treating Patients With Malignant Glioma</brief_title>
  <official_title>A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery&#xD;
      to patients who have malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose of O6-benzylguanine (O6-BG) that produces total depletion of tumor&#xD;
           O6-alkylguanine-DNA alkyltransferase (AGT) levels in more than 90% of patients with&#xD;
           cerebral anaplastic astrocytoma or glioblastoma multiforme.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicities of O6-BG in this patient&#xD;
           population.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Part I: The first cohort of 10 patients receives O6-benzylguanine (O6-BG) IV over 1 hour at&#xD;
      dose level 1 beginning 6 hours prior to surgery. If at least 3 of 10 patients in the first&#xD;
      cohort have detectable levels of O6-alkylguanine-DNA alkyltransferase (AGT), then a second&#xD;
      cohort of 10 patients receives O6-BG as above at dose level 2. Dose escalation continues&#xD;
      until at least 8 of 10 patients have undetectable AGT activity. At this point, 4 additional&#xD;
      patients are accrued. If at least 11 of 14 patients at this dose level have undetectable&#xD;
      levels of AGT, then this dose level constitutes the biologic modulatory dose of O6-BG. If&#xD;
      less than 11 of 14 patients have undetectable levels of AGT, then 10 additional patients are&#xD;
      treated at a higher dose. If at any time 3 or more patients at a dose level have detectable&#xD;
      AGT activity, accrual is stopped at that dose level and patients are treated at the next&#xD;
      higher dose level. (Part I closed to accrual effective 7/10/2000)&#xD;
&#xD;
      Part II: An additional cohort of 14 patients receives O6-BG at dose level 5 beginning 18&#xD;
      hours prior to surgery.&#xD;
&#xD;
      PROJECTED ACCRUAL: Part I of this study closed to accrual effective 7/10/2000. A total of 14&#xD;
      patients will be accrued for part II of this study at a rate of 3 patients per month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 1997</start_date>
  <completion_date type="Actual">January 1, 2009</completion_date>
  <primary_completion_date type="Actual">February 20, 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-benzylguanine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Must be undergoing a diagnostic/therapeutic craniotomy for biopsy/resection of&#xD;
             recurrent or newly diagnosed (or presumed) cerebral anaplastic astrocytoma or&#xD;
             glioblastoma multiforme&#xD;
&#xD;
               -  Patients undergoing stereotactic biopsy or partial resection are eligible&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,800/mm3&#xD;
&#xD;
          -  Platelet count at least 125,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT less than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 70 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiovascular illnesses that cannot be adequately controlled with&#xD;
&#xD;
          -  appropriate therapy or would increase risk, e.g.:&#xD;
&#xD;
          -  Severe cardiac disease such as uncontrolled arrhythmias or conduction&#xD;
&#xD;
          -  defects&#xD;
&#xD;
          -  Major problems with edema (e.g., residual leg swelling from deep venous&#xD;
&#xD;
          -  thrombosis)&#xD;
&#xD;
          -  Recent coronary artery disease&#xD;
&#xD;
          -  Poorly controlled hypertension (systolic pressure greater than 180 mm Hg,&#xD;
&#xD;
          -  diastolic pressure greater than 110 mm Hg)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other medical illnesses that cannot be adequately controlled with&#xD;
&#xD;
          -  appropriate therapy or would increase risk, e.g.:&#xD;
&#xD;
          -  Major problems with edema (e.g., Cushing's syndrome)&#xD;
&#xD;
          -  Major psychiatric illness&#xD;
&#xD;
          -  No other malignancy requiring active therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must us effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Must have failed or received no prior treatment with a nitrosourea,&#xD;
&#xD;
          -  procarbazine, or temozolomide&#xD;
&#xD;
          -  No prior O6-benzylguanine&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to greater than 10-20% of bone marrow&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent therapy for any other malignancy&#xD;
&#xD;
          -  At least 2 weeks since other prior investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Prados, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UCSF Medical Center at Parnassus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 2, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2003</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>O(6)-benzylguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

